Trial Profile
Phase II Pharmacological Study With Wee-1 Inhibitor MK-1775 Combined With Carboplatin in Patients With p53 Mutated Epithelial Ovarian Cancer and Early Relapse (< 3 Months) or Progression During Standard First Line Treatment With an Additional Safety and Preliminary Anti-tumor Activity Cohort of Wee-1 Inhibitor AZD1775 Combined With Carboplatin in Patients With Platinum Resistant TP53 Mutated Epithelial Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Carboplatin
- Indications Ovarian cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 12 Sep 2023 Last checked against ClinicalTrials.gov record.
- 31 Aug 2023 Status changed from active, no longer recruiting to completed.
- 24 May 2023 Results of an additional safety and efficacy cohort and explore predictive biomarkers for resistance and response to this combination treatment, published in the Gynecologic Oncology